143 related articles for article (PubMed ID: 37073571)
1. Exploration of a Potential Desirability of Outcome Ranking Endpoint for Complicated Intra-Abdominal Infections Using 9 Registrational Trials for Antibacterial Drugs.
Kinamon T; Gopinath R; Waack U; Needles M; Rubin D; Collyar D; Doernberg SB; Evans S; Hamasaki T; Holland TL; Howard-Anderson J; Chambers H; Fowler VG; Nambiar S; Kim P; Boucher HW
Clin Infect Dis; 2023 Aug; 77(4):649-656. PubMed ID: 37073571
[TBL] [Abstract][Full Text] [Related]
2. Improving Traditional Registrational Trial End Points: Development and Application of a Desirability of Outcome Ranking End Point for Complicated Urinary Tract Infection Clinical Trials.
Howard-Anderson J; Hamasaki T; Dai W; Collyar D; Rubin D; Nambiar S; Kinamon T; Hill C; Gelone SP; Mariano D; Baba T; Holland TL; Doernberg SB; Chambers HF; Fowler VG; Evans SR; Boucher HW
Clin Infect Dis; 2023 Feb; 76(3):e1157-e1165. PubMed ID: 36031403
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
Howard-Anderson J; Hamasaki T; Dai W; Collyar D; Rubin D; Nambiar S; Kinamon T; Leister-Tebbe H; Hill C; Geres H; Holland TL; Doernberg SB; Chambers HF; Fowler VG; Evans SR; Boucher HW;
Clin Infect Dis; 2024 Feb; 78(2):259-268. PubMed ID: 37740559
[TBL] [Abstract][Full Text] [Related]
5. Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
Popejoy MW; Long J; Huntington JA
BMC Infect Dis; 2017 May; 17(1):316. PubMed ID: 28464828
[TBL] [Abstract][Full Text] [Related]
6. Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection.
Doernberg SB; Tran TTT; Tong SYC; Paul M; Yahav D; Davis JS; Leibovici L; Boucher HW; Corey GR; Cosgrove SE; Chambers HF; Fowler VG; Evans SR; Holland TL;
Clin Infect Dis; 2019 May; 68(10):1691-1698. PubMed ID: 30321315
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
[TBL] [Abstract][Full Text] [Related]
8. Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam.
Kullar R; Wagenlehner FM; Popejoy MW; Long J; Yu B; Goldstein EJ
J Antimicrob Chemother; 2017 Mar; 72(3):900-905. PubMed ID: 27999024
[TBL] [Abstract][Full Text] [Related]
9. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
Solomkin J; Hershberger E; Miller B; Popejoy M; Friedland I; Steenbergen J; Yoon M; Collins S; Yuan G; Barie PS; Eckmann C
Clin Infect Dis; 2015 May; 60(10):1462-71. PubMed ID: 25670823
[TBL] [Abstract][Full Text] [Related]
10. Clinical response and mortality in tigecycline complicated intra-abdominal infection and complicated skin and soft-tissue infection trials.
Bassetti M; McGovern PC; Wenisch C; Meyer RD; Yan JL; Wible M; Rottinghaus ST; Quintana A
Int J Antimicrob Agents; 2015 Sep; 46(3):346-50. PubMed ID: 26155003
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Tolerability of Eravacycline in Bacteremic Patients with Complicated Intra-Abdominal Infection: A Pooled Analysis from the IGNITE1 and IGNITE4 Studies.
Felice VG; Efimova E; Izmailyan S; Napolitano LM; Chopra T
Surg Infect (Larchmt); 2021 Jun; 22(5):556-561. PubMed ID: 33201771
[No Abstract] [Full Text] [Related]
13. Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial.
Solomkin J; Evans D; Slepavicius A; Lee P; Marsh A; Tsai L; Sutcliffe JA; Horn P
JAMA Surg; 2017 Mar; 152(3):224-232. PubMed ID: 27851857
[TBL] [Abstract][Full Text] [Related]
14. The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study.
Kohno S; Bando H; Yoneyama F; Kikukawa H; Kawahara K; Shirakawa M; Aoyama N; Brown M; Paschke A; Takase A
J Infect Chemother; 2021 Feb; 27(2):262-270. PubMed ID: 33191112
[TBL] [Abstract][Full Text] [Related]
15. Novel Method Suggests Global Superiority of Short-Duration Antibiotics for Intra-abdominal Infections.
Celestin AR; Odom SR; Angelidou K; Evans SR; Coimbra R; Guidry CA; Cuschieri J; Banton KL; O'Neill PJ; Askari R; Namias N; Duane TM; Claridge JA; Dellinger EP; Sawyer RA; Cook CH
Clin Infect Dis; 2017 Oct; 65(9):1577-1579. PubMed ID: 29020201
[TBL] [Abstract][Full Text] [Related]
16. Nationwide observational study of mortality from complicated intra-abdominal infections and the role of bacterial cultures.
Tsuchiya A; Yasunaga H; Tsutsumi Y; Kawahara T; Matsui H; Fushimi K
Br J Surg; 2019 Apr; 106(5):606-615. PubMed ID: 30883708
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of tigecycline for the treatment of complicated skin and soft-tissue and intra-abdominal infections: an analysis based on five European observational studies.
Guirao X; Sánchez García M; Bassetti M; Bodmann KF; Dupont H; Montravers P; Heizmann WR; Capparella MR; Simoneau D; Eckmann C
J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii37-44. PubMed ID: 23772045
[TBL] [Abstract][Full Text] [Related]
18. IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections.
Solomkin JS; Gardovskis J; Lawrence K; Montravers P; Sway A; Evans D; Tsai L
Clin Infect Dis; 2019 Aug; 69(6):921-929. PubMed ID: 30561562
[TBL] [Abstract][Full Text] [Related]
19. Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial.
Evans SR; Knutsson M; Amarenco P; Albers GW; Bath PM; Denison H; Ladenvall P; Jonasson J; Easton JD; Minematsu K; Molina CA; Wang Y; Wong KL; Johnston SC
Clin Trials; 2020 Dec; 17(6):617-626. PubMed ID: 32666831
[TBL] [Abstract][Full Text] [Related]
20. A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections.
Sun Y; Fan J; Chen G; Chen X; Du X; Wang Y; Wang H; Sun F; Johnson MG; Bensaci M; Huntington JA; Bruno CJ
Int J Infect Dis; 2022 Oct; 123():157-165. PubMed ID: 35987467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
